Martin Shkreli, the 'Pharma Bro,' is ordered to surrender all copies of the rare Wu-Tang Clan album.

• A federal judge in New York ordered Martin Shkreli to surrender any copies of the rare Wu-Tang Clan album "Once Upon a Time in Shaolin" that he possesses.
• In 2017, Shkreli was convicted of securities fraud and subsequently forfeited to the U.S. government.

On Monday, a New York federal judge ordered Martin Shkreli to surrender any copy of the rare Wu-Tang Clan album "Once Upon a Time in Shaolin" that he still possesses, as he had previously forfeited it to the U.S. government following his conviction of securities fraud in 2017.

Judge Pamela Chen of the Brooklyn federal court prohibited Shkreli, who was released from prison in 2018, from streaming or distributing the album.

Chen on Friday held a hearing on a preliminary injunction request by PleasrDAO.

The court has ordered Shkreli to relinquish possession of the album or its contents by Friday, and to surrender any copies he currently holds.

By Sept. 30, Chen instructed Shkreli to submit a signed inventory and account detailing the nature and volume of the copies of the Album's data and files that Defendant retained, the names and contact information of the individuals to whom he distributed the data and files, the date and method of such distribution, and the amounts, source, date, and nature of any proceeds, revenues, profits, or other financial benefits made by Defendant from his distribution or playing of the Album or its contents.

The lawsuit outcome will determine whether Chen's order remains in effect.

Edward Paltzik, Shkreli's lawyer, stated to CNBC that the Order entered by the Court is a preliminary measure to maintain the perceived status quo before any discovery occurs. The Order has no impact on the final outcome of the case.

Paltzik stated that the Court did not believe that PleasrDAO would succeed on the merits or that the DAO's accusations were true, and instead decided that Mr. Shkreli's motion to dismiss should proceed without delay.

In 2017, Shkreli, 41, was found guilty in Brooklyn federal court for deceiving investors about the performance of two hedge funds he managed and for conspiring to fraudulently manipulate shares of a drug company he founded.

In 2015, Shkreli gained notoriety by increasing the price of Daraprim, a drug used to treat pregnant women, babies, and people with HIV, by over 4,000% at another pharmaceutical company he ran.